Recent Updates
Recently added Catalysts
SNDL Neutral Sentiment Score: 45/100

SNDL Inc. Condensed Consolidated Interim Financial Statements For the three and nine months ended

Key Takeaway: SNDL Inc. has released its condensed consolidated interim financial statements for the three and nine months ending September 30, 2025. The company reported a net revenue increase to CAD 693,902 for the nine-month period, with a gross profit of CAD 188,419. However, SNDL also noted a net loss attributable to its owners of CAD 25,141, reflecting ongoing challenges despite some increases in cash reserves and operating cash flow. Total assets decreased from CAD 1,349,242 to CAD 1,318,061, indicating potential financial strain.

Market Sentiment Analysis

POSITIVE FACTORS

  • Increase in cash and cash equivalents to CAD 240,581 from CAD 218,359.
  • Improved gross profit for the nine months ended compared to the previous year.
  • Cash provided by operating activities increased significantly.

CONCERNS & RISKS

  • Net loss of CAD 25,141 for the nine months ended September 30, 2025.
  • Decrease in total shareholders' equity from CAD 1,133,356 to CAD 1,099,291.
  • Significant increase in general and administrative expenses.

Full Press Release Details

Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited expressed in thousands of Canadian dollars)
Condensed Consolidated Interim Statements of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)
As at Note September 30, 2025 December 31, 2024
Assets
Current assets
Cash and cash equivalents 240,581 218,359
Restricted cash 19,798 19,815
Marketable securities 139 139
Accounts receivable 26,299 28,118
Biological assets 5 3,507 1,187
Inventory 6 125,334 127,919
Prepaid expenses and deposits 12,580 16,860
Investments 12 595 27,560
Assets held for sale 7 746 19,051
Net investment in subleases 10 2,754 2,832
432,333 461,840
Non-current assets
Long-term deposits and receivables 4,460 3,679
Right of use assets 8 122,701 115,435
Property, plant and equipment 9 152,510 145,810
Net investment in subleases 10 12,350 15,354
Intangible assets 11 59,224 61,325
Investments 12 19,089 8,427
Equity-accounted investees 13 391,146 413,124
Goodwill 124,248 124,248
Total assets 1,318,061 1,349,242
Liabilities
Current liabilities
Accounts payable and accrued liabilities 50,652 56,275
Lease liabilities 15 35,158 34,256
Derivative warrants 14 26
85,810 90,557
Non-current liabilities
Lease liabilities 15 119,971 118,017
Other liabilities 12,989 7,312
Total liabilities 218,770 215,886
Shareholders' equity
Share capital 16(b) 2,295,625 2,346,728
Warrants 667 667
Contributed surplus 66,435 57,156
Accumulated deficit (1,312,710 ) (1,323,965 )
Accumulated other comprehensive income ( AOCI ) 49,274 52,770
Total shareholders' equity 1,099,291 1,133,356
Total liabilities and shareholders' equity 1,318,061 1,349,242
Commitments and contingencies (note 25)
Subsequent events (note 26)
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)
Three months ended September 30 Nine months ended September 30
Note 2025 2024 2025 2024
Net revenue 18 244,219 236,892 693,902 662,769
Cost of sales 6 180,042 173,924 505,483 491,237
Gross profit 64,177 62,968 188,419 171,532
Investment income 19 1,777 5,577 6,162 12,817
Share of (loss) profit of equity-accounted investees 13 (234 ) (13,401 ) (4,387 ) 999
General and administrative 45,967 49,980 137,702 142,711
Sales and marketing 3,617 2,813 10,768 8,850
Depreciation and amortization 8,9,11 12,928 13,389 39,076 41,051
Share-based compensation 17 10,883 5,702 15,190 15,428
Restructuring costs 1,134 1,918 2,287 2,050
Asset impairment (recovery), net 8,9 2,051 (258 ) 2,971 2,317
Research and development 156 76 354 222
Loss (gain) on disposition of assets 34 35 (54 ) 441
Operating loss (11,050 ) (18,511 ) (18,100 ) (27,722 )
Other (expenses) income, net 20 (2,269 ) 609 (7,041 ) (4,080 )
Loss before income tax (13,319 ) (17,902 ) (25,141 ) (31,802 )
Income tax (expense) recovery (1,434 ) 2,847
Net loss (13,319 ) (19,336 ) (25,141 ) (28,955 )
Equity-accounted investees - share of other comprehensive income (loss) 13 7,709 (4,802 ) (13,250 ) 9,532
Investments at fair value through other comprehensive income ( FVOCI ) - change in fair value 12 12,940 9,754
Comprehensive income (loss) 7,330 (24,138 ) (28,637 ) (19,423 )
Net loss attributable to:
Owners of the Company (13,319 ) (19,328 ) (25,141 ) (27,654 )
Non-controlling interest (8 ) (1,301 )
(13,319 ) (19,336 ) (25,141 ) (28,955 )
Comprehensive income (loss) attributable to:
Owners of the Company 7,330 (24,130 ) (28,637 ) (18,122 )
Non-controlling interest (8 ) (1,301 )
7,330 (24,138 ) (28,637 ) (19,423 )
Net loss per common share attributable to owners of the Company
Basic and diluted 22 $ (0.05 ) $ (0.07 ) $ (0.10 ) $ (0.10 )
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
Note Share capital Warrants Contributed surplus Contingent consideration Accumulated deficit AOCI - Equity-accounted investees AOCI - Investments at FVOCI Non- controlling interest Total
Balance at December 31, 2024 2,346,728 667 57,156 (1,323,965 ) 50,906 1,864 1,133,356
Net loss (25,141 ) (25,141 )
Other comprehensive loss (income) (13,250 ) 9,754 (3,496 )
Share repurchases (51,465 ) 36,396 (15,069 )
Share-based compensation 17 9,641 9,641
Employee awards exercised 362 (362 )
Balance at September 30, 2025 2,295,625 667 66,435 (1,312,710 ) 37,656 11,618 1,099,291
Balance at December 31, 2023 2,375,950 2,260 73,014 2,279 (1,260,851 ) 19,417 17,271 1,229,340
Net loss (27,654 ) (1,301 ) (28,955 )
Other comprehensive income 9,532 9,532
Share issuances 164 164
Share issuance costs (57 ) (57 )
Share issuances by subsidiaries 52 76 128
Acquisition 3,693 3,693
Warrants expired (1,593 ) 753 (840 )
Share-based compensation 17 11,255 11,255
Employee awards exercised 3,483 (3,483 )
Distribution declared by subsidiaries 13 13
Balance at September 30, 2024 2,383,233 667 81,591 2,279 (1,288,505 ) 28,949 16,059 1,224,273
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)
Three months ended September 30 Nine months ended September 30
Note 2025 2024 2025 2024
Cash provided by (used in):
Operating activities
Net loss for the period (13,319 ) (19,336 ) (25,141 ) (28,955 )
Adjustments for:
Income tax expense (recovery) 1,434 (2,847 )
Interest and fee income 19 (1,675 ) (5,577 ) (5,849 ) (12,886 )
Change in fair value of biological assets 5 (784 ) 167 (2,559 ) (401 )
Change in fair value of inventory sold 1,313 1,313
Share-based compensation 17 10,883 5,702 15,190 15,428
Depreciation and amortization 8,9,11 13,972 13,970 42,108 42,679
Loss (gain) on disposition of assets 34 35 (54 ) 441
Inventory impairment and obsolescence 6 1,833 413 2,663 3,395
Finance costs, net 20 1,812 1,740 5,149 5,522
Change in estimate of fair value of derivative warrants (1 ) (3,848 ) (26 ) (4,348 )
Unrealized foreign exchange (gain) loss (153 ) 80 40 235
Transaction costs 164
Asset impairment (recovery), net 8,9 2,051 (258 ) 2,971 2,317
Share of loss (profit) of equity-accounted investees 13 234 13,401 4,387 (999 )
Unrealized (gain) loss on marketable securities 19 (102 ) (313 ) 69
Additions to marketable securities (327 ) 313 (327 )
Income distributions from equity-accounted investees 10,715 68 10,715
Interest received 1,409 4,496 5,628 10,317
Change in non-cash working capital 21 14,194 (13 ) (282 ) (9,722 )
Net cash provided by operating activities 31,701 22,794 45,606 30,797
Investing activities
Additions to property, plant and equipment 9 (5,185 ) (1,706 ) (8,853 ) (5,306 )
Additions to intangible assets 11 (2,421 ) (2,421 )
Additions to investments 12 (29,066 ) (16,414 ) (29,966 )
Principal payments from investments 12 129 10,114 27,293 12,382
Proceeds from disposal of investments 12 15,058 15,058
Capital refunds from equity-accounted investees 13 168
Capital distributions from equity-accounted investees 13 481 89,758 4,273 89,758
Proceeds from disposal of property, plant and equipment 166 126
Acquisitions, net of cash acquired 26 (1,000 ) (1,654 )
Change in non-cash working capital 21 39 (191 ) 10 379
Net cash provided by investing activities 10,522 66,488 20,533 63,466
Financing activities
Change in restricted cash (243 ) (324 )
Payments on lease liabilities, net 10,15 (9,920 ) (9,780 ) (29,217 ) (27,002 )
Repurchase of common shares 16(b) (3 ) (15,034 )
Proceeds from issuance of shares, net of costs (57 )
Issuance of common shares by subsidiaries 174
Change in non-cash working capital 21 57 783 334 881
Net cash used in financing activities (9,866 ) (9,240 ) (43,917 ) (26,328 )
Change in cash and cash equivalents 32,357 80,042 22,222 67,935
Cash and cash equivalents, beginning of period 208,224 182,934 218,359 195,041
Cash and cash equivalents, end of period 240,581 262,976 240,581 262,976
See accompanying notes to the condensed consolidated interim financial statements.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
1.Description of business
SNDL Inc. ( SNDL or the Company ) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. On July 25, 2022, the Company's shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from Sundial Growers Inc. to SNDL Inc. .
The Company's head office is located at 101, 17220 Stony Plain Road, Edmonton, Alberta.
The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned and franchise retail cannabis stores in certain Canadian jurisdictions where the private sale of adult-use cannabis is permitted, the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis in Canada and for export pursuant to the Cannabis Act (Canada) (the Cannabis Act ), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult-use access in Canada.
SNDL and its subsidiaries operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. ( SunStream ) (note 13), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.
The Company's liquor retail operations are seasonal in nature. Accordingly, sales will vary by quarter based on consumer spending behaviour. The Company is able to adjust certain variable costs in response to seasonal revenue patterns; however, costs such as occupancy are fixed, causing the Company to report a higher level of earnings in the third and fourth quarters. This business seasonality results in quarterly performance that is not necessarily indicative of the year's performance. The cannabis industry is a growing industry and the Company has not observed significant seasonality as of yet.
The Company's common shares trade on the Nasdaq Capital Market under the ticker symbol SNDL and on the Canadian Securities Exchange under the symbol SNDL .
In early 2025, the U.S. administration imposed certain tariffs on imports from certain countries, including Canada, and in response, the Canadian administration imposed their own tariffs on certain imports from the United States. Canada and the United States continue ongoing negotiations on a new trade and security relationship, though the scope and terms of such negotiations and the agreements they may produce, if any, are unknown. These tariff announcements and the risk of further potential retaliatory tariffs have created uncertainty, which has permeated the economic and investment outlook, impacting current economic conditions, including such issues as the inflation rate and the global supply chain. Aside from the impact on the global economy, these tariffs may continue to impact SNDL.
SNDL is continuing to monitor the evolving situation and the impacts and potential consequences on its financial position. The Company did not experience a significant impact to its financial performance during the nine months ended September 30, 2025.
2.Basis of presentation
Statement of compliance
These condensed consolidated interim financial statements ( financial statements ) have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee. These financial statements were prepared using the same accounting policies and methods as those disclosed in the
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
annual consolidated financial statements for the year ended December 31, 2024. These financial statements should be read in conjunction with the annual consolidated financial statements for the Company for the year ended December 31, 2024.
Certain prior period amounts have been reclassified to conform to current year presentation. Specifically, changes to investments have been separated into additions to investments and principal payments from investments on the condensed consolidated interim statement of cash flows.
These financial statements were approved and authorized for issue by the board of directors of the Company (the Board ) on November 3, 2025.
3.Business acquisitions
On July 5, 2024, the Company announced that it had entered into a purchase agreement with Indiva Limited ( Indiva ) and its direct and indirect subsidiaries (collectively with Indiva, the Indiva Group ), pursuant to which the Company offered to purchase all of the issued and outstanding shares of Indiva and the business and assets of the Indiva Group (the Indiva Transaction ) for consideration comprising of a credit bid of all of the indebtedness of the Indiva Group owing to the Company, the retention of certain liabilities of the Indiva Group, and cash payments sufficient to repay certain priority indebtedness of the Indiva Group and costs associated with the Indiva Group's proceedings under the Companies' Creditors Arrangement Act (Canada).
On November 4, 2024, the Company announced that it had successfully closed the Indiva Transaction for consideration of approximately $21.1 million, comprised of the extinguishment of $20.7 million in total debt owing by Indiva to the Company and a cash payment of approximately $0.4 million.
The Company has engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed. The purchase price allocation is not final as the Company is continuing to obtain and verify information required to determine the fair value of certain assets and liabilities and the amount of deferred income taxes, if any, arising on their recognition.
Due to the inherent complexity associated with valuations and the timing of the acquisition, the amounts below are provisional and subject to adjustment. The fair value of consideration paid was as follows:
Provisional
Extinguishment of term loan 18,923
Extinguishment of debtor-in-possession loan 1,750
Cash 385
21,058
The preliminary fair value of the assets and liabilities acquired was as follows:
Provisional
Cash 3
Accounts receivable 4,057
Inventory 4,860
Prepaid expenses and deposits 205
Right of use assets 562
Property, plant and equipment 21,213
Accounts payable and accrued liabilities (4,100 )
Lease liabilities (286 )
Total identifiable net assets acquired 26,514
Bargain purchase gain (5,456 )
21,058
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
The excess of the aggregate fair value of the identifiable net assets acquired over the fair value of the consideration was $5.46 million, which was recorded as a bargain purchase gain included in other expenses, net, in the consolidated statements of loss and comprehensive loss for the year ended December 31, 2024. The bargain purchase gain was primarily due to the fair value adjustments on the identifiable property, plant and equipment and net working capital acquired.
As new information is obtained within one year of the date of acquisition, about facts and circumstances that existed at the date of acquisition, the accounting for the acquisition will be revised. All such adjustments will be recorded to the bargain purchase gain in the period that the adjustment is identified. For the three and nine months ended September 30, 2025, no changes were made to the preliminary fair value of the assets and liabilities acquired or the bargain purchase gain.
4.Segment information
The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.
Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis products and accessories through corporate-owned and franchised retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as Corporate .
Cannabis Retail Cannabis Operations Intersegment Eliminations Cannabis Total Liquor Retail Investments Corporate Total
As at September 30, 2025
Total assets (1) 211,092 207,865 418,957 322,158 410,830 166,116 1,318,061
Nine months ended September 30, 2025
Net revenue (2) 246,960 107,544 (51,391 ) 303,113 390,789 693,902
Gross profit 63,974 23,452 87,426 100,993 188,419
Operating income (loss) 22,329 (3,628 ) 18,701 24,276 1,775 (62,852 ) (18,100 )
Earnings (loss) before income tax 20,194 (3,772 ) 16,422 21,356 1,775 (64,694 ) (25,141 )
Three months ended September 30, 2025
Net revenue (2) 85,021 37,389 (17,579 ) 104,831 139,388 244,219
Gross profit 22,465 5,008 27,473 36,704 64,177
Operating income (loss) 9,105 (5,434 ) 3,671 11,222 1,543 (27,486 ) (11,050 )
Earnings (loss) before income tax 8,086 (5,458 ) 2,628 10,374 1,543 (27,864 ) (13,319 )
(1)As at September 30, 2025, cash and cash equivalents have been allocated to Corporate from Investments.
(2)The Company has eliminated $51.4 million for the nine months ended September 30, 2025 and $17.6 million for the three months ended September 30, 2025 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Cannabis Retail Cannabis Operations Intersegment Eliminations Cannabis Total Liquor Retail Investments (1) Corporate Total
As at December 31, 2024
Total assets 195,823 230,021 425,844 326,061 577,522 19,815 1,349,242
Nine months ended September 30, 2024
Net revenue (2) 228,519 72,378 (39,307 ) 261,590 401,179 662,769
Gross profit 58,337 11,725 70,062 101,470 171,532
Operating income (loss) 7,255 (1,728 ) 5,527 22,456 13,711 (69,416 ) (27,722 )
Earnings (loss) before income tax 4,637 (2,133 ) 2,504 19,314 13,136 (66,756 ) (31,802 )
Three months ended September 30, 2024
Net revenue (2) 81,144 25,007 (13,824 ) 92,327 144,565 236,892
Gross profit 20,710 5,307 26,017 36,951 62,968
Operating income (loss) 4,395 (703 ) 3,692 11,795 (7,824 ) (26,174 ) (18,511 )
Earnings (loss) before income tax 3,328 (65 ) 3,263 10,900 (7,824 ) (24,241 ) (17,902 )
(1)Total assets include cash and cash equivalents.
(2)The Company has eliminated $39.3 million for the nine months ended September 30, 2024 and $13.8 million for the three months ended September 30, 2024 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.
Geographical disclosure
As at September 30, 2025, the Company had non-current assets related to credit investments in the United States of $391.1 million (December 31, 2024 $413.1 million). For the nine months ended September 30, 2025, share of profit of equity-accounted investees related to operations in the United States was a loss of $4.4 million (nine months ended September 30, 2024 profit of $1.0 million). All other non-current assets relate to operations in Canada and revenues from external customers relate to operations in Canada.
The Company's biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:
As at September 30, 2025 December 31, 2024
Balance, beginning of year 1,187 429
Increase in biological assets due to capitalized costs 12,088 7,243
Net change in fair value of biological assets 2,559 (892 )
Transferred to inventory upon harvest (12,327 ) (5,593 )
Balance, end of period 3,507 1,187
Biological assets are valued in accordance with International Accounting Standard 41 Agriculture and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
The Company estimates the harvest yields for cannabis at various stages of growth. As at September 30, 2025, it is estimated that the Company's biological assets will yield approximately 13,795 kilograms (December 31, 2024 4,500 kilograms) of dry cannabis when harvested. During the nine months ended September 30, 2025, the Company harvested 19,681 kilograms of dry cannabis (nine months ended September 30, 2024 5,529 kilograms).
As at September 30, 2025 December 31, 2024
Retail liquor 74,907 73,538
Retail cannabis 18,540 21,783
Harvested cannabis
Raw materials, packaging and components 11,802 13,030
Work-in-progress 15,237 16,058
Finished goods 4,848 3,510
125,334 127,919
During the three and nine months ended September 30, 2025, inventories of $177.7 million and $504.1 million were recognized in cost of sales as an expense (three and nine months ended September 30, 2024 $173.3 million and $488.4 million).
During the three and nine months ended September 30, 2025, the Company recognized inventory write downs of $1.8 million and $2.7 million (three and nine months ended September 30, 2024 $0.4 million and $3.4 million).
7.Assets held for sale
At September 30, 2025, assets held for sale were measured at their fair value less costs to sell and comprised of the following:
As at September 30, 2025 December 31, 2024
Olds facility 18,800
Extraction equipment 746 251
746 19,051
The Olds facility, located in Olds, Alberta, had a primary purpose to cultivate cannabis for the adult-use market. Upon closing the Olds facility, management committed to a plan to sell the Olds facility and classified the asset as available for sale. During the nine months ended September 30, 2025, management concluded that the Olds facility no longer met certain criteria for assets held for sale due to secondary commercial real estate market conditions in Alberta and therefore reclassified it back to property, plant and equipment.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
8.Right of use assets
Cost
Balance at December 31, 2024 217,251
Additions 9,331
Renewals, remeasurements and dispositions 20,315
Balance at September 30, 2025 246,897
Accumulated depreciation and impairment
Balance at December 31, 2024 101,816
Depreciation 23,895
Impairment reversal (1,515 )
Balance at September 30, 2025 124,196
Net book value
Balance at December 31, 2024 115,435
Balance at September 30, 2025 122,701
For the nine months ended September 30, 2025, the Company recorded the following net impairment reversals on right of use assets:
Reporting Segment
Three months ended Liquor retail Cannabis retail Total
March 31, 2025 (468 ) (468 )
June 30, 2025 (586 ) (586 )
September 30, 2025 (461 ) (461 )
(1,515 ) (1,515 )
Refer to note 9 for the significant assumptions applied in the impairment test.
For the nine months ended September 30, 2024, the Company recorded the following net impairment (reversals) losses on right of use assets:
Reporting Segment
Three months ended Liquor retail Cannabis retail Total
March 31, 2024 (159 ) 1,756 1,597
June 30, 2024 (132 ) (283 ) (415 )
September 30, 2024 (192 ) 98 (94 )
(483 ) 1,571 1,088
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2025
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
9.Property, plant and equipment
Land Production facilities Leasehold improvements Equipment Construction in progress Total
Cost
Balance at December 31, 2024 9,454 51,251 78,250 108,903 2,571 250,429
Additions 1,244 2,796 5,736 9,776
Transfers from CIP 2,571 (2,571 )
Transfer from (to) assets held for sale 18,800 (507 ) 18,293
Dispositions (6 ) (2,285 ) (2,291 )
Balance at September 30, 2025 9,454 70,051 82,059 108,907 5,736 276,207
Accumulated depreciation and impairment
Balance at December 31, 2024 4,960 38,126 61,533 104,619
Depreciation 1,254 6,700 8,158 16,112
Impairment (recovery) 689 4,943 (862 ) (284 ) 4,486
Dispositions (6 ) (1,514 ) (1,520 )
Balance at September 30, 2025 689 11,157 43,958 67,893 123,697
Net book value
Balance at December 31, 2024 9,454 46,291 40,124 47,370 2,571 145,810
Balance at September 30, 2025 8,765 58,894 38,101 41,014 5,736 152,510

Frequently Asked Questions

What is the net loss for three months ended September 30, 2025?

The net loss for the three months ended September 30, 2025, is $13,319,000.

How did the shareholders' equity change by September 30, 2025?

By September 30, 2025, shareholders' equity decreased to $1,099,291,000.

What was total assets reported at September 30, 2025?

Total assets at September 30, 2025, were $1,318,061,000.

What were the net revenues for the nine months ended September 30, 2025?

Net revenues for the nine months ended September 30, 2025, were $693,902,000.

What were the total liabilities reported as of September 30, 2025?

Total liabilities as of September 30, 2025, were $218,770,000.

Last updated: Nov 4, 2025